
Sandoz has completed the acquisition of the US biosimilar CIMERLI®
Sandoz has completed the acquisition of the US biosimilar CIMERLI® (ranibizumab-eqrn) from Coherus BioSciences, Inc, ahead of anticipated timelines. The acquisition builds on the leading Sandoz ophthalmic platform in the US and lays an even stronger foundation for future product…